Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alveoli and Alveolar Ducts01:26

Alveoli and Alveolar Ducts

The respiratory zone of the human body, which stands in contrast to the conducting zone, comprises the structures that actively participate in the exchange of gases. The initiation of this zone is marked by the terminal bronchioles converging into respiratory bronchioles, the tiniest bronchiole classification. The respiratory bronchioles give way to the alveolar ducts that opens into a congregation of alveoli. Actively involved in gas exchange, alveoli resemble tiny sacs similar to clusters of...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
Chronic Obstructive Pulmonary Disease II: Emphysema01:23

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Emergency room visits for asthma and the reported outcomes: The PASS survey by the CRISALIS network].

Revue des maladies respiratoires·2025
Same author

Evaluation of oral immunotherapy in hazelnut allergy: Pediatric experience in Toulouse.

Allergy·2024
Same author

Nivolumab in patients with advanced renal cell carcinoma in France: interim results of the observational, real-world WITNESS study.

ESMO open·2024
Same author

Improved nationwide survival of sarcoma patients with a network of reference centers.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Regorafenib in patients with relapsed advanced or metastatic chordoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study.

ESMO open·2023
Same author

[Guidelines for the management of chronic cough in adults].

Revue des maladies respiratoires·2023

Related Experiment Video

Updated: Jun 28, 2026

Evaluating In Vitro DNA Damage Using Comet Assay
10:43

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

[Alveolo-interstitial pneumonia due to Temozolamide].

L Guilleminault1, P Carré, K de Luca

  • 1Service de Pneumologie, CHU de Tours, Université François Rabelais de Tours, France. guillel@free.fr

Revue Des Maladies Respiratoires
|October 24, 2008
PubMed
Summary

Temozolomide, used for glioblastoma, can cause drug-induced pneumonia. This case highlights the importance of recognizing this rare but serious pulmonary toxicity in patients undergoing chemotherapy.

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Related Experiment Videos

Last Updated: Jun 28, 2026

Evaluating In Vitro DNA Damage Using Comet Assay
10:43

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Area of Science:

  • Oncology
  • Pulmonology
  • Pharmacology

Background:

  • Temozolomide is a standard alkylating agent for glioblastoma treatment, often combined with radiotherapy.
  • Glioblastoma multiforme is a highly aggressive primary brain tumor requiring intensive therapeutic strategies.

Observation:

  • A 56-year-old woman developed alveolo-interstitial pneumonia following Temozolomide chemotherapy for glioblastoma.
  • Clinical presentation included dyspnea, with CT scans revealing interstitial opacities and bronchoalveolar lavage showing lymphocytosis.

Findings:

  • The patient's pneumonia was diagnosed as drug-induced, attributed to Temozolomide based on temporal association and exclusion of infectious causes.
  • Microbiological investigations did not identify any bacterial pathogens.

Implications:

  • This case underscores the potential for Temozolomide-induced pulmonary toxicity, a rare but significant adverse event.
  • Pulmonary adverse effects of Temozolomide warrant inclusion in product information to guide clinical monitoring and patient care.